Want to see ITRMF full AI Analyst Report?
Top Page
Iterum Therapeutics
(OTC:ITRMF)
Select Model
Select Model
Rating:43Neutral
Price Target:
$0.31
▼(-8.53% Downside)
Action:Upgraded
Date:12/30/25
The score is held down primarily by weak financial fundamentals (minimal revenue, persistent losses, cash burn, and negative equity) and bearish technicals (price below major moving averages with negative MACD). The earnings call adds some support due to early launch traction and 2026 revenue guidance, but this is tempered by the need for additional capital, while the Nasdaq listing compliance issue adds further downside risk.
Positive Factors
Patent expansion (China & Mexico)
Extended patents in China and Mexico through 2039–2041 materially lengthen market exclusivity in key international jurisdictions. This strengthens long-term commercial upside, supports pricing power versus generics, and enhances licensing or partnering optionality across global markets.
Negative Factors
Negative shareholders' equity and elevated leverage
Negative equity and debt that exceeds assets constrain financial flexibility and increase refinancing and dilution risk. This capital-structure weakness can limit investment in commercial scale-up or R&D and raises vulnerability to adverse funding conditions over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Patent expansion (China & Mexico)
Extended patents in China and Mexico through 2039–2041 materially lengthen market exclusivity in key international jurisdictions. This strengthens long-term commercial upside, supports pricing power versus generics, and enhances licensing or partnering optionality across global markets.
Read all positive factors
Iterum Therapeutics (ITRMF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.48M
Dividend YieldN/A
Average Volume (3M)813.22K
Price to Earnings (P/E)―
Beta (1Y)2.86
Revenue GrowthN/A
EPS Growth62.61%
CountryUS
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.75
Shares Outstanding52,835,200
10 Day Avg. Volume1,119,323
30 Day Avg. Volume813,222
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-8.54
Price to Sales (P/S)0.00
P/FCF Ratio-1.30
Enterprise Value/Market Cap16.63
Enterprise Value/Revenue63.07
Enterprise Value/Gross Profit-36.82
Enterprise Value/Ebitda-1.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)$9.38M
Iterum Therapeutics Business Overview & Revenue Model
Company Description
Iterum Therapeutics plc, an Irish pharmaceutical company founded in Dublin in 2015, is dedicated to the development and commercialization of treatments for bacterial infections that are resistant to existing drugs. Operating in Ireland, Bermuda, a...
How the Company Makes Money
Iterum Therapeutics makes money through the development and potential commercialization of its primary product candidate, sulopenem. The company's revenue model is expected to include income from the sale of sulopenem upon receiving regulatory app...
Iterum Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 390.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -668.00K | -254.00K | -1.75M | -1.80M | -2.10M | -161.00K |
| EBITDA | -23.07M | -21.73M | -34.58M | -39.97M | -83.20M | -36.01M |
| Net Income | -26.96M | -24.77M | -38.37M | -44.43M | -91.56M | -52.01M |
Balance Sheet | ||||||
| Total Assets | 32.50M | 44.59M | 26.26M | 66.83M | 91.51M | 32.79M |
| Cash, Cash Equivalents and Short-Term Investments | 11.00M | 24.13M | 23.93M | 60.80M | 81.34M | 14.57M |
| Total Debt | 33.73M | 45.53M | 18.96M | 30.10M | 30.43M | 48.08M |
| Total Liabilities | 39.88M | 48.68M | 32.66M | 38.83M | 41.27M | 83.35M |
| Stockholders Equity | -7.38M | -4.08M | -6.40M | 28.00M | 50.23M | -50.56M |
Cash Flow | ||||||
| Free Cash Flow | -19.93M | -26.77M | -39.34M | -18.54M | -15.90M | -54.54M |
| Operating Cash Flow | -19.91M | -26.77M | -39.33M | -18.47M | -15.84M | -54.53M |
| Investing Cash Flow | 1.09M | 18.21M | 23.34M | 13.96M | -54.59M | -11.00K |
| Financing Cash Flow | 16.27M | 26.69M | 1.03M | -1.82M | 83.13M | 64.47M |
Iterum Therapeutics Technical Analysis
Negative
0.34
Price Trends
0.05
Negative
0.09
Negative
0.29
Negative
Market Momentum
>-0.01
Positive
40.02
Neutral
33.89
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ITRMF, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.04, above the 50-day MA of 0.05, and above the 200-day MA of 0.29, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.02 is Neutral, neither overbought nor oversold. The STOCH value of 33.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ITRMF.
Iterum Therapeutics Risk Analysis
Iterum Therapeutics disclosed 88 risk factors in its most recent earnings report. Iterum Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Iterum Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $77.69M | -1.92 | 233.93% | ― | -61.71% | -11.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $61.02M | -1.67 | -117.24% | ― | 476.71% | 70.23% | |
47 Neutral | $217.57M | -2.91 | -194.74% | ― | 160.53% | 12.32% | |
46 Neutral | $49.27M | -1.31 | -93.08% | ― | 110.08% | 76.04% | |
45 Neutral | $24.64M | -0.39 | -226.10% | ― | ― | 71.62% | |
43 Neutral | $1.48M | -0.10 | ― | ― | ― | 62.61% |
* Healthcare Sector Average
ITRMF
Iterum Therapeutics
0.03
-1.05
-97.59%
CVM
Cel-Sci
1.35
-2.47
-64.66%
CLNN
Clene
6.25
2.49
66.22%
XLO
Xilio Therapeutics
9.20
-1.21
-11.66%
CAMP
CAMP4 Therapeutics Corporation
4.34
2.80
181.82%
RADX
Radiopharm Theranostics Limited Sponsored ADR
4.28
0.08
1.90%
Iterum Therapeutics Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge
Negative
Dec 12, 2025
On December 11, 2025, Iterum Therapeutics received a notification from Nasdaq indicating that it no longer meets the listing requirements due to its market value of listed securities falling below $35 million for 30 consecutive business days. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.